Full-Time
Develops portable nitric oxide therapies
No salary listed
Waltham, MA, USA
In Person
Third Pole Therapeutics develops medical devices and therapies for heart and lung conditions. Its flagship portable inhaled nitric oxide device delivers nitric oxide gas to improve blood flow and oxygen delivery, while eNOfit is a wearable platform that continuously and controllably administers nitric oxide. Revenue comes from selling devices to hospitals and through partnerships with other medical companies, and the company differentiates itself by combining portable NO delivery with a wearable drug-delivery platform and maintaining strict quality and regulatory standards (ISO 13485:2016). The goal is to improve patient outcomes and broaden treatment options in cardiopulmonary medicine by developing, manufacturing, and commercializing advanced nitric oxide therapies.
Company Size
11-50
Company Stage
Debt Financing
Total Funding
$106.4M
Headquarters
Waltham, Massachusetts
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Wellness Program
Mental Health Support
Remote Work Options
Flexible Work Hours
Conference Attendance Budget
Professional Development Budget
Stock Options
401(k) Retirement Plan
401(k) Company Match
Health Insurance
Dental Insurance
Vision Insurance
Disability Insurance
Life Insurance
Paid Vacation
Paid Holidays
Paid Sick Leave
Parental Leave
Family Planning Benefits
Fertility Treatment Support
Adoption Assistance
Childcare Support
Elder Care Support
Professional Certification Support
Tuition Reimbursement
Training Programs
Mentorship Program
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Third Pole has filed a notice of an exempt offering of securities to raise $10 Million in New Equity and Debt Financing. Third Pole has filed a notice of an exempt offering of securities to raise $10 Million in New Equity and Debt Financing.According to filings with the U.S. Securities and Exchange Commission, Third Pole is raising up to $10,000,000.00 in new funding. Sources indicate that as part of senior management President, Basil Athenson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About Third PoleThird Pole, Inc. is a US-based company developing next generation life-saving cardiopulmonary therapies. We are building on our teams legacy in inhaled nitric oxide (NO), the current standard of care, to develop next generation life-saving heart and lung therapies
In 2017, Third Pole won a Johnson & Johnson Innovation award for the iNO-generating device.
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator.
Funding will support the final development phase prior to planned 2023 FDA submission of the company's "breakthrough" designated eNOcare™ hospital deviceWALTHAM, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator.Bill Athenson, CEO of Third Pole, stated, "We are thrilled to receive this investment, which raises Third Pole Therapeutics' series B financing and commitments to date to over $85M. I am particularly pleased to welcome this strategic investor and partner given our closely aligned missions. This investment and partnership will accelerate the entry of eNOcare™, our advanced portable inhaled nitric oxide (iNO) device, into the iNO hospital market." Mr. Athenson continued, "This significant investment in Third Pole Therapeutics follows considerable diligence of our engineering and regulatory readiness and serves as a strong endorsement of our technology and team's ability to deliver critical care systems that exceed safety and performance requirements established by regulatory bodies and the most demanding care professionals. We are targeting a 2023 FDA submission for our eNOcare™ hospital system into the existing and underpenetrated $600 million iNO hospital market."Bill Heiden, Third Pole's Chairman added, "This strategic investment in Third Pole Therapeutics is directly aligned with both organization's mission to advance unique, disruptive, cost-effective solutions that improve outcomes in heart and lung-failure patients
Form D Friday is a Boston Business Journal feature highlighting regulatory filings from Boston-area companies raising capital for new projects or expanding their businesses.